VX-765: Selective Caspase-1 Inhibition for Inflammatory Pathway Research

Executive Summary: VX-765 is a potent, orally absorbed inhibitor of caspase-1 and is metabolized in vivo to VRT-043198, its active form. It selectively blocks the maturation and secretion of pro-inflammatory cytokines IL-1β and IL-18, but not IL-6, IL-8, TNFα, or IL-α, making it highly specific for the caspase-1 pathway (Bourne et al., 2025). VX-765 has demonstrated efficacy in reducing inflammation and cytokine secretion in multiple preclinical models and is under investigation for therapeutic use in epilepsy and inflammatory diseases (APExBIO product page). The compound is insoluble in water but exhibits high solubility in DMSO and ethanol, and is stable when stored desiccated at -20°C. Recent studies confirm its selectivity profile and provide quantitative benchmarks for its inhibitory activity against caspases involved in both apoptosis and pyroptosis (Bourne et al., 2025).

Biological Rationale

Caspases are cysteine proteases that orchestrate key processes in cell death and inflammation. Among these, caspase-1 (interleukin-1 converting enzyme, ICE) is central to the maturation of IL-1β and IL-18, which are critical mediators of the innate immune response (Bourne et al., 2025). Activation of caspase-1 occurs through inflammasome complexes in response to pathogen-associated or damage-associated molecular patterns (PAMPs/DAMPs). Upon activation, caspase-1 cleaves the pro-forms of IL-1β and IL-18, enabling their secretion and downstream signaling. Dysregulated caspase-1 activity is implicated in autoimmune and inflammatory diseases, as well as in pathogen-induced pyroptosis, a lytic form of programmed cell death in macrophages. Thus, selective inhibition of caspase-1 offers a strategy to modulate inflammation without broadly suppressing immune function.

Mechanism of Action of VX-765

VX-765 is a pro-drug that is metabolized in vivo to the active inhibitor VRT-043198. This metabolite binds to the active site of caspase-1, preventing its autoproteolytic activation and substrate processing. The inhibition is highly selective, with minimal activity against other caspases such as caspase-3, -6, and -9, which mediate apoptotic pathways (Bourne et al., 2025). VX-765 blocks the conversion of inactive pro-IL-1β and pro-IL-18 to their mature forms, thereby preventing their secretion. Notably, VX-765 also shows moderate inhibition of caspase-4 and caspase-8 at micromolar concentrations, but remains most potent against caspase-1. This specificity enables researchers to dissect the role of caspase-1 in inflammation and cell death without confounding effects from general caspase inhibition. For more on the signaling context, see this article, which details RNA Pol II interactions; this current review instead focuses on cytokine maturation and comparative selectivity.

Evidence & Benchmarks

• VX-765 inhibits human caspase-1 with an IC₅₀ of ~0.8 μM in standardized in vitro enzyme assays (pH 7.5, 25°C, DMSO vehicle) (Bourne et al., 2025).
• Inhibits caspase-4 with a lower potency (IC₅₀ ~7 μM) under identical conditions (Bourne et al., 2025).
• VX-765 reduces IL-1β and IL-18 secretion in collagen-induced arthritis mouse models, resulting in decreased inflammation scores and cytokine levels (APExBIO).
• Prevents CD4 T-cell pyroptosis in HIV-infected lymphoid tissues in a dose-dependent manner (50–200 μM, ex vivo, 37°C) (APExBIO).
• No significant inhibition of apoptotic caspases (e.g., caspase-3, -6, -9) observed at concentrations up to 100 μM (Bourne et al., 2025).
• VX-765 is orally bioavailable in rodents and non-human primates, with measurable plasma concentrations and pharmacodynamic effects at doses ≥10 mg/kg (APExBIO).

Applications, Limits & Misconceptions

VX-765 is widely used in preclinical research to dissect the role of caspase-1 in inflammation, cytokine biology, and pyroptosis. Applications include studies in rheumatoid arthritis, neuroinflammation, and infectious disease models. It is also used to probe the contribution of the caspase signaling pathway in cell death and cytokine modulation. For a discussion on VX-765’s emerging role in blood-brain barrier research, see this article, whereas this current review emphasizes direct cytokine and cell death endpoints in peripheral tissues.

Common Pitfalls or Misconceptions

• VX-765 does not inhibit all caspases; it is selective for caspase-1, with moderate inhibition of caspase-4 and caspase-8 only at higher concentrations (Bourne et al., 2025).
• It is not effective as a general anti-inflammatory for all cytokines—IL-6, IL-8, TNFα, and IL-α secretion remain unaffected (APExBIO).
• VX-765 does not directly block apoptosis; its primary action is on the pyroptosis pathway (Bourne et al., 2025).
• Solubility limitations: VX-765 is insoluble in water; improper dissolution may lead to inconsistent dosing in experimental setups (APExBIO).
• Incorrect storage (e.g., moisture or temperatures above -20°C) can degrade the compound and affect results (APExBIO).

Workflow Integration & Parameters

For optimal results, VX-765 should be dissolved in DMSO (≥313 mg/mL) or ethanol (≥50.5 mg/mL with ultrasonic aid). Working solutions should be prepared fresh and used within short-term windows to avoid degradation. Store VX-765 desiccated at -20°C. Enzyme inhibition assays are typically run in buffered conditions at pH 7.5 (Tris-HCl, 50 mM) with reducing agents to stabilize enzyme activity. Cell-based assays require careful titration to avoid off-target effects, especially at concentrations exceeding 10 μM. For a comparative discussion on VX-765's role in cell death pathway dissection, see this related review; the present article provides updated benchmarks and practical considerations for reagent use.

Conclusion & Outlook

VX-765, available from APExBIO as the A8238 kit, remains a gold-standard tool for selective caspase-1 inhibition and mechanistic dissection of inflammatory pathways. Its specificity for IL-1β and IL-18 processing makes it indispensable for current models of pyroptosis and cytokine-driven disease. Future research may further clarify its potential for clinical translation and its applicability to complex multicellular immune circuits. For broader context on VX-765’s impact on inflammation research and therapeutic development, see this forward-looking perspective, which addresses translational and competitive aspects beyond those discussed here.